Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

lncRNA‑CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia

lncRNA‑CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia The aim of the present study was to examine the expression and clinical significance of long non‑coding RNA (lncRNA)‑CCDC26 in patients with acute myeloid leukemia (AML), and to investigate the potential functions of CCDC26. The Gene Expression Omnibus database and reverse transcription‑quantitative polymerase chain reaction analysis were used to detect the expression levels of CCDC26 in patients with AML and healthy volunteers. Clinical data for 93 patients with AML were collected to analyze the clinical significance of CCDC26. Weighted gene co‑expression network analysis (WGCNA), a protein‑protein interaction (PPI) network, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were used to examine the functions of CCDC26. The expression levels of CCDC26 in the initially diagnosed and relapsed patients with AML were significantly upregulated compared with the control group. The upregulated expression level of CCDC26 in patients with AML was significantly associated with age, anemia, risk stratification and remission. Furthermore, patients with a high CCDC26 expression level had a poorer overall survival (P=0.0105). In addition, the area under the curve (AUC)1year and AUC2year of CCDC26 for overall survival were 0.722 and 0.686, respectively. WGCNA, PPI network and KEGG pathway analysis revealed that CCDC26 was involved in the regulation of a number of biological processes. lncRNA‑CCDC26 may serve as a novel biomarker for monitoring the progression and predicting the clinical outcome of AML. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology Letters Spandidos Publications

lncRNA‑CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia

Download PDF
9 pages

Loading next page...
 
/lp/spandidos-publications/lncrna-ccdc26-as-a-novel-biomarker-predicts-prognosis-in-acute-myeloid-D0YlbDJdxc

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Spandidos Publications
Copyright
Copyright \xC2\xA9 2019 Spandidos Publications
ISSN
1792-1074

Abstract

The aim of the present study was to examine the expression and clinical significance of long non‑coding RNA (lncRNA)‑CCDC26 in patients with acute myeloid leukemia (AML), and to investigate the potential functions of CCDC26. The Gene Expression Omnibus database and reverse transcription‑quantitative polymerase chain reaction analysis were used to detect the expression levels of CCDC26 in patients with AML and healthy volunteers. Clinical data for 93 patients with AML were collected to analyze the clinical significance of CCDC26. Weighted gene co‑expression network analysis (WGCNA), a protein‑protein interaction (PPI) network, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were used to examine the functions of CCDC26. The expression levels of CCDC26 in the initially diagnosed and relapsed patients with AML were significantly upregulated compared with the control group. The upregulated expression level of CCDC26 in patients with AML was significantly associated with age, anemia, risk stratification and remission. Furthermore, patients with a high CCDC26 expression level had a poorer overall survival (P=0.0105). In addition, the area under the curve (AUC)1year and AUC2year of CCDC26 for overall survival were 0.722 and 0.686, respectively. WGCNA, PPI network and KEGG pathway analysis revealed that CCDC26 was involved in the regulation of a number of biological processes. lncRNA‑CCDC26 may serve as a novel biomarker for monitoring the progression and predicting the clinical outcome of AML.

Journal

Oncology Letters – Spandidos Publications

Published: Sep 24, 2019

There are no references for this article.